Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
Coherus BioSciences (NASDAQ: CHRS) has scheduled its fourth quarter and full year 2024 financial results announcement for March 10, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. ET on the same day, where management will discuss financial results and provide a business update.
Investors and interested parties can pre-register for the conference call through a provided link to receive dial-in information and a personal PIN. A live webcast will be available, and both the press release containing the financial results and an archived version of the webcast will be accessible through the company's investor relations website.
Coherus BioSciences (NASDAQ: CHRS) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per 10 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conference call e un webcast alle 17:00 ET dello stesso giorno, durante il quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento sull'attività.
Gli investitori e le parti interessate possono preregistrarsi per la conference call tramite un link fornito per ricevere le informazioni di accesso e un PIN personale. Sarà disponibile un webcast dal vivo e sia il comunicato stampa contenente i risultati finanziari che una versione archiviata del webcast saranno accessibili tramite il sito web delle relazioni con gli investitori dell'azienda.
Coherus BioSciences (NASDAQ: CHRS) ha programado el anuncio de los resultados financieros del cuarto trimestre y del año completo 2024 para el 10 de marzo de 2025, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica y un webcast a las 5:00 p.m. ET el mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización del negocio.
Los inversores y partes interesadas pueden preregistrarse para la conferencia telefónica a través de un enlace proporcionado para recibir la información de acceso y un PIN personal. Habrá un webcast en vivo, y tanto el comunicado de prensa que contiene los resultados financieros como una versión archivada del webcast estarán disponibles a través del sitio web de relaciones con inversores de la empresa.
Coherus BioSciences (NASDAQ: CHRS)는 2025년 3월 10일에 시장 종료 후 2024년 4분기 및 전체 연도 재무 결과 발표를 예정하고 있습니다. 회사는 같은 날 오후 5시 ET에 컨퍼런스 콜과 웹캐스트를 개최하여 경영진이 재무 결과를 논의하고 사업 업데이트를 제공할 것입니다.
투자자 및 이해관계자는 제공된 링크를 통해 컨퍼런스 콜에 사전 등록하여 전화 접속 정보와 개인 PIN을 받을 수 있습니다. 실시간 웹캐스트가 제공되며 재무 결과를 포함한 보도 자료와 웹캐스트의 아카이브 버전은 회사의 투자자 관계 웹사이트를 통해 접근할 수 있습니다.
Coherus BioSciences (NASDAQ: CHRS) a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 10 mars 2025, après la fermeture du marché. L'entreprise organisera une conférence téléphonique et un webcast le même jour à 17h00 ET, où la direction discutera des résultats financiers et fournira une mise à jour sur les activités.
Les investisseurs et les parties intéressées peuvent se préinscrire à la conférence téléphonique via un lien fourni pour recevoir les informations de connexion et un code PIN personnel. Un webcast en direct sera disponible, et à la fois le communiqué de presse contenant les résultats financiers et une version archivée du webcast seront accessibles via le site web des relations avec les investisseurs de l'entreprise.
Coherus BioSciences (NASDAQ: CHRS) hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 10. März 2025 nach Marktende angesetzt. Das Unternehmen wird am selben Tag um 17:00 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, bei dem das Management die finanziellen Ergebnisse besprechen und ein Update zum Geschäft geben wird.
Investoren und Interessierte können sich über einen bereitgestellten Link für die Telefonkonferenz vorregistrieren, um die Einwahlinformationen und eine persönliche PIN zu erhalten. Ein Live-Webcast wird verfügbar sein, und sowohl die Pressemitteilung mit den finanziellen Ergebnissen als auch eine archivierte Version des Webcasts werden über die Website der Investor Relations des Unternehmens zugänglich sein.
- None.
- None.
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Conference Call Information
When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BIddb737c625d842e0867fa22a43106197
Webcast: https://edge.media-server.com/mmc/p/3dwbidfe
The press release with the fourth quarter and full year 2024 financial results and related materials will be available at https://investors.coherus.com/ before the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations following the conclusion of the live conference call.
Please dial in 15 minutes early to ensure a timely connection to the call.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Coherus
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and is developing an innovative immuno-oncology pipeline that is expected to synergize with its proven commercial capabilities in oncology.
Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in three ongoing clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, cytolytic anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors, including HNSCC.
Coherus Contact Information
Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com
FAQ
When will Coherus BioSciences (CHRS) release its Q4 and full year 2024 earnings?
What time is the Coherus BioSciences (CHRS) Q4 2024 earnings call?
How can investors access Coherus BioSciences (CHRS) Q4 2024 earnings call?
Where can I find Coherus BioSciences (CHRS) Q4 2024 earnings materials?
